Fragile X Syndrome – Epidemiology – Epidemiology – Fragile X Syndrome – Mature Markets

Clarivate Epidemiology’s coverage of fragile X syndrome (FXS) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of FXS for each country, as well as annualized case counts projected to the national population.

All patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.

Clarivate Epidemiology’s FXS forecast will answer the following questions:

• Of all people with FXS, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of FXS over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts the following FXS patient populations:

• Total prevalent cases of FXS.
• Diagnosed prevalent cases of FXS.
• Diagnosed prevalent cases of FXS with autism spectrum disorder.
• Total prevalent cases of FXS premutation.

Note: Coverage may vary by country.